BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 10365114)

  • 1. 5-Fluorouracil plus high dose levofolinic acid and oral hydroxyurea for the treatment of primary hepatocellular carcinomas: results of a phase II multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Gebbia V; Maiello E; Serravezza G; Giotta F; Testa A; Borsellino N; Pezzella G; Colucci G
    Anticancer Res; 1999; 19(2B):1407-10. PubMed ID: 10365114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
    Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of refractory metastatic breast cancer with 5-fluorouracil and levofolinic acid as 48 hours continuous venous infusion.
    Gebbia V; Mauceri G; Testa A; Tirrito M; Varvara F; Cucchiara A; Borsellino N; Girlando A; Ferrara M; Caruso F
    Anticancer Res; 1999; 19(3B):2289-92. PubMed ID: 10472346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of refractory metastatic breast cancer with 5-fluorouracil plus levofolinic acid as continuous venous infusion: a phase II study.
    Gebbia V; Borsellino N; Testa A; Tirrito M; Varvara F; Cucchiara A; Mauceri G; Girlando A; Ferrara M; Caruso F
    Anticancer Res; 1999; 19(4C):3553-7. PubMed ID: 10629652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vinorelbine and 5-fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer: an analysis of results in clinical practice of the Gruppo Oncologico Italia Meridionale (GOIM).
    Gebbia V; Caruso M; Borsellino N; Ajello R; Tirrito ML; Chiarenza M; Valenza R; Verderame F; Varvara F; Marrazzo A; Bajardi E; Ferrao F; Bordonaro R; Tralongo P
    Anticancer Res; 2006; 26(4B):3143-50. PubMed ID: 16886648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
    Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS
    Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma.
    Cheng AL; Chen YC; Yeh KH; Chuang SE; Chen BR; Chen DS
    Cancer; 1996 Mar; 77(5):872-7. PubMed ID: 8608477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
    Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
    Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
    Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
    Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors.
    Kaubisch A; Kaleya R; Haynes H; Rozenblit A; Wadler S
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):337-40. PubMed ID: 14704829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.
    Wolff K; Wein A; Reulbach U; Männlein G; Brückl V; Meier C; Ostermeier N; Schwab SA; Horbach T; Hohenberger W; Hahn EG; Boxberger F
    Anticancer Drugs; 2009 Mar; 20(3):165-73. PubMed ID: 19125117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.
    Ikeda M; Okusaka T; Ueno H; Takezako Y; Morizane C
    Cancer; 2005 Feb; 103(4):756-62. PubMed ID: 15637692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hepatocellular carcinoma using arterial chemoembolization with degradable starch microspheres and continuous arterial infusion of 5-fluorouracil.
    Ishida K; Hirooka M; Hiraoka A; Kumagi T; Uehara T; Hiasa Y; Horiike N; Onji M
    Jpn J Clin Oncol; 2008 Sep; 38(9):596-603. PubMed ID: 18772170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
    Lin CC; Hsu CH; Huang CY; Cheng AL; Vogelzang NJ; Pu YS
    J Urol; 2007 Jan; 177(1):84-9; discussion 89. PubMed ID: 17162009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).
    Link K; Happich K; Schirner I; Jüngert B; Brückl V; Männlein G; Brückl WM; Merkel S; Göhl J; Hohenberger W; Hahn EG; Wein A
    Anticancer Res; 2004; 24(1):385-91. PubMed ID: 15015625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
    Ando E; Tanaka M; Yamashita F; Kuromatsu R; Yutani S; Fukumori K; Sumie S; Yano Y; Okuda K; Sata M
    Cancer; 2002 Aug; 95(3):588-95. PubMed ID: 12209752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
    Lee J; Park JO; Kim WS; Park SH; Park KW; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC; Joh J; Kim K; Jung CW; Park YS; Im YH; Kang WK; Lee MH; Park K
    Cancer Chemother Pharmacol; 2004 Nov; 54(5):385-90. PubMed ID: 15248028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly levofolinic acid and 5-fluorouracil plus hydroxyurea in metastatic gastrointestinal adenocarcinomas.
    Gebbia V; Valenza R; Testa A; Cipolla C; Latteri M; Curto G; Comande S; Buccellato C; Gebbia N
    Am J Clin Oncol; 1994 Dec; 17(6):485-9. PubMed ID: 7977165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.